Tags: SOCMA Member News
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
September 16, 2020
Lonza and Sheba Medical Center announced the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonza’s Cocoon® Platform.
September 8, 2020
President Trump visited Volunteer Pastilles, LLC Lake Charles plant on Saturday, August 29, while he was in Lake Charles assessing the damage from Hurricane Laura.
September 2, 2020
Sun Chemical released its Summer 2020 Regulatory Newsletter for customers which is now available.
August 31, 2020
Sun Chemical has organized a Corporate Sustainability Committee to further strengthen its approach to addressing the sustainability needs of the packaging industry.
August 17, 2020
Solvay signed a global distribution agreement with Strem Chemicals, Inc., a manufacturer of high-purity specialty products, to fulfill commercial sampling and research requests for its specialty phosphorus products.
August 12, 2020
Kodiak Sciences, a clinical-stage biopharmaceutical company specializing in novel ophthalmic therapies, and Lonza announced today that the companies have signed a long-term contract for manufacturing KSI-301, an Antibody Biopolymer Conjugate (ABC) that is a potential first-line treatment for retinal vascular diseases.
August 10, 2020
Pilot Chemical Company named Frank D. Nataro as the company’s new North America Sales Manager. Nataro will oversee all sales activities of the North American sales team and will be responsible for developing and executing sales strategy that delivers results in line with Pilot’s growth objectives.
August 4, 2020
Lonza today reported strong Group sales growth of 7.7%3 and a resilient CORE EBITDA margin of 29.1%. The results reflect Lonza Group’s robustness to the challenges and uncertainties arising from the COVID-19 pandemic in H1.
July 24, 2020
Monument Chemical, a global producer of specialty chemicals, announced today that Paul Raymond has been named Chief Executive Officer (CEO).
July 2, 2020
